S
Shanghai Chengfan Pharmaceutical
VelaVigo is a start-up specializing in macromolecular biopharmaceuticals
About Shanghai Chengfan Pharmaceutical
Shanghai Chengfan Pharmaceutical Co., Ltd., operating under the brand name Velavigo, is a clinical-stage biopharmaceutical entity headquartered in Shanghai. The company was established in 2021. Velavigo concentrates its resources on the discovery and development of therapeutic agents for autoimmune diseases and oncological conditions.
The firm's strategic direction is centered on creating a pipeline of globally competitive drug candidates. A primary asset in their portfolio is V-106, a small molecule inhibitor targeting TYK2, which is currently undergoing clinical trials. This drug candidate is being investigated for its potential in treating a range of autoimmune disorders. Velavigo maintains full intellectual property rights for V-106.
Velavigo's operational model involves advancing its proprietary drug candidates through the various stages of clinical development. The company's focus on the autoimmune and oncology markets positions it within two significant and growing sectors of the pharmaceutical industry. The business generates value by developing novel therapies that address unmet medical needs within these areas.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Huangpu, China
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 75.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Jul 2025 | $60M | $240M | NLVC · Highlight Capital · Zoo Capital · Shanghai Healthcare Capital | ↗ |
| SEEDOther financing | Jan 2025 | $50M | $200M | Delian Capital · Panacea Venture · SHC Shanghai Biomedical Fund · Legend Star | ↗ |
Growth signals
Latest recorded traffic for Shanghai Chengfan Pharmaceutical is 350 monthly website visits, down 30% over the last three months. Shanghai Chengfan Pharmaceutical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed16 investors entered at this stage
Vertex Ventures China
Panacea Venture- HCHonghui Capital
Med-Fine Capital
SHC Shanghai Biomedical Fund
Delian Capital
Legend Star
Highlight Capital- EFEverjoy Fortune
Shunwei Capital
NLVC
Zoo Capital- SCShanghai Healthcare Capital
Everest Venture Capital
Hankang Capital- SHShanghai Lingang New Area Investment Holdings
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Chengfan Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Chengfan Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.